{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:23:56Z","timestamp":1785900236914,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Science and Technology Commission Research Project","award":["17411953200"],"award-info":[{"award-number":["17411953200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00277-023-05138-0","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T19:23:50Z","timestamp":1677007430000},"page":"795-800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic value of interim 18F-FDG PET\/CT in adult follicular lymphoma treated with R-CHOP"],"prefix":"10.1007","volume":"102","author":[{"given":"Na","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-7985","authenticated-orcid":false,"given":"Jinhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"1","key":"5138_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","volume":"14","author":"W Hanel","year":"2021","unstructured":"Hanel W, Epperla N (2021) Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol 14(1):104","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5138_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2021.278766","volume":"107","author":"G Cartron","year":"2022","unstructured":"Cartron G, Trotman J (2022) Time for an individualized approach to first-line management of follicular lymphoma. Haematologica 107(1):7\u201318. https:\/\/doi.org\/10.3324\/haematol.2021.278766","journal-title":"Haematologica"},{"issue":"1","key":"5138_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A et al (2019) Follicular lymphoma. Nat Rev Dis Primers 5(1):83","journal-title":"Follicular lymphoma. Nat Rev Dis Primers"},{"issue":"20","key":"5138_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"1","key":"5138_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjh.17404","volume":"195","author":"A Barraclough","year":"2021","unstructured":"Barraclough A, Bishton M, Cheah CY et al (2021) The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. Br J Haematol 195(1):15\u201324. https:\/\/doi.org\/10.1111\/bjh.17404","journal-title":"Br J Haematol"},{"issue":"6","key":"5138_CR6","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1080\/10428194.2020.1716222","volume":"61","author":"BS Imber","year":"2020","unstructured":"Imber BS, Chau K, Goldberg E et al (2020) Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. Leuk Lymphoma 61(6):1500\u20131503. https:\/\/doi.org\/10.1080\/10428194.2020.1716222","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"5138_CR7","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1002\/cncr.33772","volume":"127","author":"ME Juweid","year":"2021","unstructured":"Juweid ME, Mueller M, Alhouri A et al (2021) Positron emission tomography\/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: an update. Cancer 127(20):3727\u20133741. https:\/\/doi.org\/10.1002\/cncr.33772","journal-title":"Cancer"},{"issue":"3","key":"5138_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1148\/radiol.2020192056","volume":"295","author":"FZ Mokrane","year":"2020","unstructured":"Mokrane FZ, Chen A, Schwartz LH et al (2020) Performance of CT compared with 18F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology 295(3):651\u2013661. https:\/\/doi.org\/10.1148\/radiol.2020192056","journal-title":"Radiology"},{"issue":"16","key":"5138_CR9","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.3390\/cancers13163952","volume":"13","author":"A Gallamini","year":"2021","unstructured":"Gallamini A, Kurlapski M, Zaucha JM (2021) FDG-PET\/CT for the management of post-chemotherapy residual mass in Hodgkin lymphoma. Cancers (Basel) 13(16):3952. https:\/\/doi.org\/10.3390\/cancers13163952","journal-title":"Cancers (Basel)"},{"issue":"8","key":"5138_CR10","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","volume":"30","author":"N Aide","year":"2020","unstructured":"Aide N, Fruchart C, Nganoa C et al (2020) Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol 30(8):4623\u20134632","journal-title":"Eur Radiol"},{"issue":"1","key":"5138_CR11","doi-asserted-by":"publisher","first-page":"CD012643","DOI":"10.1002\/14651858.CD012643.pub3","volume":"1","author":"A Aldin","year":"2020","unstructured":"Aldin A, Umlauff L, Estcourt LJ et al (2020) Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev 1(1):CD012643. https:\/\/doi.org\/10.1002\/14651858.CD012643.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5138_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.120.244145","volume":"62","author":"J Rekowski","year":"2021","unstructured":"Rekowski J, H\u00fcttmann A, Schmitz C et al (2021) Interim PET evaluation in diffuse large B-Cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the \u0394SUVmax method. J Nucl Med 62(1):37\u201342. https:\/\/doi.org\/10.2967\/jnumed.120.244145","journal-title":"J Nucl Med"},{"issue":"8","key":"5138_CR13","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2967\/jnumed.120.255034","volume":"62","author":"L Kurch","year":"2021","unstructured":"Kurch L, H\u00fcttmann A, Georgi TW et al (2021) Interim PET in diffuse large B-cell lymphoma. J Nucl Med 62(8):1068\u20131074. https:\/\/doi.org\/10.2967\/jnumed.120.255034","journal-title":"J Nucl Med"},{"issue":"11","key":"5138_CR14","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1007\/s00259-021-05310-6","volume":"48","author":"W Qin","year":"2021","unstructured":"Qin W, Jiang X, You J et al (2021) Deauville score evaluation of interim PET\/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging 48(11):3347\u20133350","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5138_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2967\/jnumed.121.262117","volume":"63","author":"JJ Eertink","year":"2022","unstructured":"Eertink JJ, Pfaehler EAG, Wiegers SE et al (2022) Quantitative radiomics features in diffuse large B-cell lymphoma: does segmentation method matter? J Nucl Med 63(3):389\u2013395. https:\/\/doi.org\/10.2967\/jnumed.121.262117","journal-title":"J Nucl Med"},{"issue":"4","key":"5138_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/cancers14041018","volume":"14","author":"S Genta","year":"2022","unstructured":"Genta S, Ghilardi G, Cascione L et al (2022) Integration of baseline metabolic parameters and mutational profiles predicts long-term response to first-line therapy in DLBCL patients: a post hoc analysis of the SAKK38\/07 Study. Cancers (Basel) 14(4):1018. https:\/\/doi.org\/10.3390\/cancers14041018","journal-title":"Cancers (Basel)"},{"issue":"7","key":"5138_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","volume":"107","author":"L Kostakoglu","year":"2022","unstructured":"Kostakoglu L, Mattiello F, Martelli M et al (2022) Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica 107(7):1633\u20131642. https:\/\/doi.org\/10.3324\/haematol.2021.278663","journal-title":"Haematologica"},{"issue":"3","key":"5138_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.remnie.2022.03.002","volume":"41","author":"A D\u00edaz-Silv\u00e1n","year":"2022","unstructured":"D\u00edaz-Silv\u00e1n A, Ot\u00f3n-S\u00e1nchez LF, Caresia-Ar\u00f3ztegui AP et al (2022) Clinical application of [18F]FDG PET\/CT in follicular lymphoma. Rev Esp Med Nucl Imagen Mol (Engl Ed) 41(3):202\u2013212. https:\/\/doi.org\/10.1016\/j.remnie.2022.03.002","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"issue":"4","key":"5138_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2967\/jnumed.121.262324","volume":"63","author":"AC Lo","year":"2022","unstructured":"Lo AC, James LP, Prica A et al (2022) PET-based staging is cost-effective in early-stage follicular lymphoma. J Nucl Med 63(4):543\u2013548. https:\/\/doi.org\/10.2967\/jnumed.121.262324","journal-title":"J Nucl Med"},{"issue":"11","key":"5138_CR20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood.2020008243","volume":"139","author":"J Trotman","year":"2022","unstructured":"Trotman J, Pettitt AR (2022) Is it time for PET-guided therapy in follicular lymphoma? Blood 139(11):1631\u20131641. https:\/\/doi.org\/10.1182\/blood.2020008243","journal-title":"Blood"},{"issue":"4","key":"5138_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13139-019-00602-0","volume":"53","author":"SH Boo","year":"2019","unstructured":"Boo SH, Joo HO, Kwon SJ et al (2019) Predictive value of interim and end-of-therapy 18F-FDG PET\/CT in patients with follicular lymphoma. Nucl Med Mol Imaging 53(4):263\u2013269","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"5138_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.4143\/crt.2018.649","volume":"51","author":"JH Liang","year":"2019","unstructured":"Liang JH, Zhang YP, Xia J et al (2019) Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat 51(4):1479\u20131487. https:\/\/doi.org\/10.4143\/crt.2018.649","journal-title":"Cancer Res Treat"},{"key":"5138_CR23","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.2147\/CMAR.S216445","volume":"11","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhao Z, Li J et al (2019) Prognostic values of baseline, interim and end-of therapy 18F-FDG PET\/CT in patients with follicular lymphoma. Cancer Manag. Res. 11:6871\u20136885. https:\/\/doi.org\/10.2147\/CMAR.S216445","journal-title":"Cancer Manag. Res."},{"issue":"8","key":"5138_CR24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12149-014-0874-1","volume":"28","author":"Z Lu","year":"2014","unstructured":"Lu Z, Lin M, Downe P et al (2014) The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med 28(8):805\u2013811","journal-title":"Ann Nucl Med"},{"issue":"1","key":"5138_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37(1):181\u2013200","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"5138_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.hoc.2019.03.003","volume":"33","author":"K Welaya","year":"2019","unstructured":"Welaya K, Casulo C (2019) Follicular lymphoma: redefining prognosis, current treatment options, and unmet needs. Hematol Oncol Clin North Am 33(4):627\u2013638. https:\/\/doi.org\/10.1016\/j.hoc.2019.03.003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"5138_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","volume":"34","author":"JR Cerhan","year":"2020","unstructured":"Cerhan JR (2020) Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am 34(4):631\u2013646. https:\/\/doi.org\/10.1016\/j.hoc.2020.02.001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"5138_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjh.12562","volume":"163","author":"MH Shirley","year":"2013","unstructured":"Shirley MH, Sayeed S, Barnes I et al (2013) Incidence of haematological malignancies by ethnic group in England, 2001-7. Br. J. Haematol. 163(4):465\u2013477. https:\/\/doi.org\/10.1111\/bjh.12562","journal-title":"Br. J. Haematol."},{"key":"5138_CR29","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.blre.2021.100865","volume":"50","author":"P Mozas","year":"2021","unstructured":"Mozas P, Rivero A, L\u00f3pez-Guillermo A (2021) Past, present and future of prognostic scores in follicular lymphoma. Blood Rev 50:100865. https:\/\/doi.org\/10.1016\/j.blre.2021.100865","journal-title":"Blood Rev"},{"key":"5138_CR30","doi-asserted-by":"publisher","first-page":"103418","DOI":"10.1016\/j.critrevonc.2021.103418","volume":"164","author":"J Jelicic","year":"2021","unstructured":"Jelicic J, Stauffer Larsen T, Bukumiric Z et al (2021) The clinical applicability of current prognostic models in follicular lymphoma: a systematic review. Crit Rev Oncol Hematol 164:103418. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103418","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"5138_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"issue":"10","key":"5138_CR32","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s10147-019-01482-2","volume":"24","author":"M Tatsumi","year":"2019","unstructured":"Tatsumi M, Isohashi K, Matsunaga K et al (2019) Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol 24(10):1292\u20131300","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"5138_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/hematology.2021000264","volume":"2021","author":"C Casulo","year":"2021","unstructured":"Casulo C (2021) Follicular lymphoma: is there an optimal way to define risk? Hematology Am Soc Hematol Educ Program 2021(1):313\u2013319. https:\/\/doi.org\/10.1182\/hematology.2021000264","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"5138_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3):316\u2013327. https:\/\/doi.org\/10.1002\/ajh.25696","journal-title":"Am J Hematol"},{"issue":"31","key":"5138_CR35","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37(31):2815\u20132824","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05138-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05138-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05138-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T21:28:11Z","timestamp":1678397291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05138-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05138-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study. The Shanghai General Hospital Research Ethics Committee has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of retrospective study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"For this type of retrospective study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}